Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.

Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogeneity of molecular findings in different biopsies even within the same individual with lung cancer.

[powerpress]